{"filing":{"accession_number":"0001104659-26-106554","cik":"0001818838","ticker":"ADAG","company_name":"Adagene Inc.","form":"6-K","filing_date":"2026-09-10","report_date":"2026-09-10","primary_document":"tm2624950d1_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1818838/000110465926106554/tm2624950d1_6k.htm"},"events":[{"id":32535,"run_id":29896,"accession_number":"0001104659-26-106554","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Adagene announced that Third Arc Bio selected the first lead candidate under an amended strategic collaboration agreement, with broadened scope including Third Arc Bio's sponsorship and funding of clinical development and increased total potential milestone payments to Adagene. This represents a material operational and strategic development—a significant milestone in an existing partnership with enhanced commercial terms—but does not fit the discrete event categories of M\u0026A, debt issuance, or other specific financial/governance events. The amendment to the collaboration terms and the lead candidate selection constitute a material operational partnership development.","company_name":"Adagene Inc.","ticker":"ADAG","filing_date":"2026-09-10","form":"6-K","submitted_at":null,"items":[{"id":35727,"accession_number":"0001104659-26-106554","item_number":"EX-99.1","item_title":"tm2624950d1_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Adagene announced that Third Arc Bio selected the first lead candidate under an amended strategic collaboration agreement, with broadened scope including Third Arc Bio's sponsorship and funding of clinical development and increased total potential milestone payments to Adagene. This represents a material operational and strategic development—a significant milestone in an existing partnership with enhanced commercial terms—but does not fit the discrete event categories of M\u0026A, debt issuance, or other specific financial/governance events. The amendment to the collaboration terms and the lead candidate selection constitute a material operational partnership development.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-10T12:01:41.743571+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35727,"accession_number":"0001104659-26-106554","item_number":"EX-99.1","item_title":"tm2624950d1_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Adagene announced that Third Arc Bio selected the first lead candidate under an amended strategic collaboration agreement, with broadened scope including Third Arc Bio's sponsorship and funding of clinical development and increased total potential milestone payments to Adagene. This represents a material operational and strategic development—a significant milestone in an existing partnership with enhanced commercial terms—but does not fit the discrete event categories of M\u0026A, debt issuance, or other specific financial/governance events. The amendment to the collaboration terms and the lead candidate selection constitute a material operational partnership development.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-10T12:01:41.743571+00:00","company_name":"Adagene Inc.","ticker":"ADAG","filing_date":"2026-09-10"}]}